Beam Therapeutics Inc. Common Stock

$29.8
USD
Last updated on --.
24h volume1.41M
24h highest30.2600 USD
24h lowest28.8100 USD
24h Price movement+4.05%

BEAM recent prices

24 Hours
+4.05%+$1.160
30 days
+1.81%+$0.527
60 days
+29.07%+$6.450
90 days
+2.67%+$0.772

Key data

Previous close28.6400 USD
Market cap2.79B USD
Volume1.41M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount0.22500 USD
Next ex-dividend dateFeb 4, 2014
Next payment dateMar 3, 2014
EPS diluted (TTM)-0.63000 USD
Net income (FY)-65.04M USD
Revenue (FY)164.01M USD
Last report dateMay 7, 2026

About Beam Therapeutics Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersCAMBRIDGE
Employees (FY)522.00
Revenue per employee (FY)314.20K USD
Net income per employee (FY)-124.60K USD
Listed onNasdaq
Official website

BEAM conversion tables

BEAMBEAM
USDUSD
0.5 BEAM14.9 USD
1 BEAM29.8 USD
5 BEAM149 USD
10 BEAM298 USD
USDUSD
BEAMBEAM
0.5 USD0.016779 BEAM
1 USD0.033557 BEAM
5 USD0.16779 BEAM
10 USD0.33557 BEAM

FAQ

BEAM is trading at $29.80, +4.05% over the last 24 hours. Track live moves on the price chart at the top of this page.
The BEAM stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. BEAM is currently trading at $29.80, +4.05% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on BEAM price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. BEAM's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from BEAM; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against BEAM's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Beam Therapeutics Inc. Common Stock's market cap is currently 2.79B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume1.41M
24h highest30.2600 USD
24h lowest28.8100 USD
24h Price movement+4.05%
BEAMBEAM
USDUSD
Start trade with BEAM Perpetual